"
Team:Potsdam Bioware/Biobricks/All Biobricks
From 2012.igem.org
(→Antibody Biobricks) |
(→Characterization:) |
||
| Line 52: | Line 52: | ||
</table> | </table> | ||
====Characterization:==== | ====Characterization:==== | ||
| + | =====Expression of Smaller Construct in CHO Cells===== | ||
| + | 1. transiently transfected | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | 2. stably transfected | ||
===Mutation Biobricks=== | ===Mutation Biobricks=== | ||
Revision as of 23:50, 26 September 2012
Contents |
All Biobricks
As the project is divided into three subproject, the resulting biobricks are listet & characterized in the three categories. Furthermore the Biobricks for the new RFC "Potsdam Standard" are listed.
For detailed information on parts design, sequence, composites click the BioBrick numbers
Antibody Biobricks
All antibody module BioBricks for the smaller construct were designed out of already existing parts and BioBricks and were expanded with further functional units by assembly PCR. The advanced antibody construct was derived by de novo synthesis based on sequence information provided by GenBank and UniProt and by one already existing Biobrick part. The gene synthesis construct was optimized for expression in CHO cell and used as template for all subsequently derived BioBricks by PCR.
| [http://partsregistry.org/Part:BBa_K929100 BBa_K929100] Anti-EGFR scFv425 |
The single chain fragment (scFV425) specifically binds to the epidermal growth factor receptor (EGFR) domain 3. The part has a shortened N-terminal FLAG-tag sequence of five amino acids (DYKDE) for purification and detection. |
| [http://partsregistry.org/Part:BBa_K929101 BBa_K929101] Anti-EGFR scFv425 with TEV site, transmembrane region an eYFP |
The Biobrick BBa_K929101 is an extended version of the Biobrick BBa_K929100 and is composed of the already existing human EGFR (ErbB-1) signal peptide (BBa_K157001), the scFv anti-EGFR-domain-3, a TEV recognition site (according to life technologies AcTEV TM Protease manual), the transmembrane domain: transmembrane domain of B-cell receptor with glycine-serine linker (BBa_K157010) and the enhanced YFP ( BBa_E0030) reporter. The composite part was derived by PCR assembly. |
| [http://partsregistry.org/Part:BBa_K929102 BBa_K929102] Anti-GFP Nanobody with IgG kappa signal peptide and IgG1 Fc domain |
This part represents an antibody unit composed of a IgG kappa signal peptide (UniProt: P01601), an anti-GFP nanobody (PDB: 3OGO) and an IgG1 Fc domain (UniProt: P01857). |
| [http://partsregistry.org/Part:BBa_K929103 BBa_K929103] B-cell transmembrane region with mCherry and TEV site, framed by LoxP |
This part represents the switchable membrane anchoring region of or antibody construct (BBa_K929107) and consists of the TEV recognition site, the modified transmembrane domain of B-cell receptor with a shortened linker (modified BBa_K157010), the mCherry reporter and two framing LoxP sites. |
| [http://partsregistry.org/Part:BBa_K929104 BBa_K929104] Anti-GFP Nanobody |
The green fluorescent protein (GFP)-nanobody is a single-chain VHH antibody domain which shows specific binding activity against GFP (PDB: 3OGO). |
| [http://partsregistry.org/Part:BBa_K929105 BBa_K929105] IgG1 Fc domain |
A human immunoglobulin gamma-1 heavy chain constant region (IGHG1) was added to the construct and enables the direct interaction of the antibody unit with the Fc receptor and complement proteins (UniProt: P01857). |
| [http://partsregistry.org/Part:BBa_K929106 BBa_K929106] B-cell transmembrane region with mCherry |
This part is a composed part of the transmembrane domain of a B-cell receptor (modified BBa_K157010)fused to the mCherry reporter for detection of cellular localization. |
| [http://partsregistry.org/Part:BBa_K929107 BBa_K929107] Anti-GFP, IgG1 Fc with TEV site, TMR, mCherry, framed by LoxP |
The antibody construct consists of two major building blocks represented by the actual antibody unit ( BBa_K929102) and the switchable membrane anchoring region (BBa_K929103). The antibody unit is represented by the human Ig kappa chain V-I region signal peptide (UniProt: P01601), the anti-GFP Nanobody (PDB: 3OGO) and the Fc region (UniProt: P01857). TEV protease recognition site, 2 LoxP sites, the B-cell receptor transmembrane domain (modified BBa_K157010) and the mCherry reporter display the switchable membrane anchoring region. |
Characterization:
Expression of Smaller Construct in CHO Cells
1. transiently transfected
2. stably transfected
Mutation Biobricks
All the Mutation Biobricks are improved/modified versions of the wildtype AID that was available as a Biobrick ([http://partsregistry.org/Part:BBa_K103001 BBa_K103001]). AID is known to be responsible for somatic hypermutation and the class-switch recombination of immunoglobulin in B cells. This enzyme of 28 kDa originally occurs in B cells but does also show activity after transfection into CHO cells. AID induces the deamination of cytidine to uridine at actively transcribed single strand DNA. The replacement of cytidine by uridine leads to a mismatch during DNA replication and integrates a single base substitution predominantly in the immunoglobulin genes.
Therefore this enzymes was used in our project for diversification of antibodies.With PCR and cloning we developed AID`s for the differnt requirements.
| [http://partsregistry.org/Part:BBa_K929000 BBa_K929000] AID with CMV promoter and hGH-polyadenylation signal sequence |
CMV-promoter & hGH polyadenylationsequence were added to the wildtype AID for strong expression. |
| [http://partsregistry.org/Part:BBa_K929001 BBa_K929001] modified_AID without NES, with NLS and Kozak sequence |
To improve the mutation rate the AID was located into the nucleus, because there it mutates transcribed DNA. Therefor an aditional NLS(Nuclear Localization Sequence)was added and the naturally occurring NES(Nuclear Exprot Sequence) was removed.For stronger Expression an Kozak Sequence was added. To fuse modified AID((C-terminal of mod. AID) with RFC 25 parts, we added an AgeI restriction site. |
| [http://partsregistry.org/Part:BBa_K929002 BBa_K929002] modified_AID with CMV and hGH-polyA |
For strong expression of the previously described part an CMV-promoter and hGH polyadenylation sequence were added. |
| [http://partsregistry.org/Part:BBa_K929004 BBa_K929004] modified_AID+eGFP |
The modified AID was fused with eGFP to check 1.)the tranfection success 2.)the cellular lokalization of the improved AID and 3.) to select transfected cells via FACS. |
| [http://partsregistry.org/Part:BBa_K929003 BBa_K929003]modified AID with CMV, hGH-polyA and eGFP |
For strong expression of the previously described part an CMV-promoter and hGH polyadenylation sequence were added. |
Characterization:
Mutation rate in CHO-cells:
We checked the mutation rate of wildtype AID([http://partsregistry.org/part:BBa_K929000 BBa_K929000]), modified AID([http://partsregistry.org/part:BBa_K929002 BBa_K929002]) and modified AID+eGFP([http://partsregistry.org/part:BBa_K929003 BBa_K929003]) (all expressed with CMV-promoter and hGHpolyA). Therefor we cotransfected CHO cells with a single chain construct and one of the AID versions. After certain expression time we purified the the single chain plasmids and transformed them into E.coli to enrich the mutated plasmids. After overnight culture and purification of the transformed plasmids, samples where sequenced.
There is a significant higher mutation rate when wildtype AID, modified AID or modified AID-eGFP is added, compared to the same experiment without AID. Surprisingly, the mutation rate of wt AID is two times higher than the mutation rate of the modified AID or modified AID-eGFP (Fig. 2). This observation is contrary to our expectation. The modified AID+eGFP is located in the nucleus (Fig. 3), that means our construct works and should have a higher mutation rate. One possible explanation is that the modified AID has a very high mutation rate and therefore the transfected cells die or inactivate the plasmid like it was observed for the wildtype AID (Martin and Scharff (2002)).
Green fluorescence reporter:
The modified AID was fused with eGFP to check 1.)the tranfection success 2.)the cellular lokalization of the improved AID and 3.) to select transfected cells via FACS.
- Transfection success and cellular localization:
The fluorescence microscope images(Fig. 3) show transfected cells A)with "modified AID+eGFP" (BBa_K929003)and B)with "modified AID+eGFP" (BBa_K929003) and a mCherry labeled nanobody construct (BBa_K929107)]]. "Modified AID+eGFP" (BBa_K929003)proved to be located in the nucleus. This shows that the deletion of the NES(Nuclear Export Sequence) and the addition of an NLS(Nuclear Localization Sequence) leads to an accumulation in the nucleus as it was planed. Therefore we would expect an increased mutation rate with "modified AID+eGFP" but as described above the experimental setup possible can not reflect this. It is also shown that transfected cells(green nucleus, Fig. 3 A&B) can be discriminated from not transfected (grey, Fig. 3). This can be used for a fast selection of transfected cells via FACS. Fig. 3 B shows that "modified AID+eGFP" can be used in combination with an other fluorescence labeld construct (mCherry labeled nanobody construct ,BBa_K929107) and co transfected cells can be easily found or selected via FACS.
Virus Biobricks
| [http://partsregistry.org/Part:BBa_K929000 BBa_K929200] N-terminal sortase motif linked to AAV2-VP2 with Myc-tag, kozak and CMV |
... |
| [http://partsregistry.org/Part:BBa_K929001 BBa_K929201] N-terminal sortase motif linked to AAV2-VP2 with kozak and CMV |
... |
| [http://partsregistry.org/Part:BBa_K929002 BBa_K929202] EGF-Receptor_3rd domain with PelB leadersequence, His-tag and C-terminal Sortase motif |
... |
Potsdam Standard Biobricks
